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The processing of visual stimuli from retina to higher cortical areas has been extensively studied in 
the human brain. In Huntington’s disease (HD), an inherited neurodegenerative disorder, it is 
suggested that visual processing deficits are present in addition to more characteristic signs such as 
motor disturbances, cognitive dysfunction, and behavioral changes. Visual deficits are clinically 
important because they influence overall cognitive performance and have implications for daily 
functioning. 
 
The aim of this review is to summarize current literature on clinical visual deficits, visual cognitive 
impairment, and underlying visual cortical changes in HD patients. A literature search was conducted 
using the electronic database of PubMed/Medline.  
 
This review shows that changes of the visual system in patients with HD were not the primary focus 
of currently published studies. Still, early atrophy and alterations of the posterior cerebral cortex 
was frequently observed, primarily in the associative visual cortical areas such as the lingual and 
fusiform gyri, and lateral occipital cortex. Changes were even present in the premanifest phase, 
before clinical onset of motor symptoms, suggesting a primary region for cortical degeneration in 
HD. Although impairments in visuospatial processing and visual perception were reported in early 
disease stages, heterogeneous cognitive batteries were used, making a direct comparison between 
studies difficult. The use of a standardized battery of visual cognitive tasks might therefore provide 
more detailed information regarding the extent of impairments in specific visual domains. Further 
research could provide more insight into clinical, functional, and pathophysiological changes of the 






Many regions of the human brain are involved in processing visual stimuli, from the retina to cortical 
brain areas. The organization and function of the visual cortex has been extensively studied in 
primates, both in macaques and healthy human adults.1,2 Visual field mapping using functional 
Magnetic Resonance Imaging (fMRI) showed that approximately 20-30% of the human brain is 
directly or indirectly involved in visual processing.3,4 Incoming visual stimuli are transmitted from the 
retina through the afferent visual pathway via the optic nerve and optic tract, to the lateral 
geniculate nucleus in the thalamus.5 Then, via the optic radiation, signals reach the primary visual 
cortex in the occipital lobe and eventually the associative (secondary and tertiary) visual cortices for 
further processing.5  
 
Figure 1 Visual cortex in human brain 
 
Schematic lateral and medial overview of cortical regions involved in the processing of visual stimuli in the human brain. 
Stimuli pass the retina via the optic tract to the primary visual cortex (V1) and secondary visual cortex (V2) for basic 
processing (i.e. shape and contrast). Although there are no clear demarcations among the regions of the posterior cortex, it 
is clear that higher-level visual processing occurs in the regions surrounding the primary visual cortex, which are divided 
into visual areas V3, V4 and V5. The ventral pathway runs through the medial part of Brodmann area 19, located in the 
anterior medial occipito-temporal gyrus, towards Brodmann area 37 (or V4) which is located in the caudal two-thirds of the 
lateral occipito-temporal gyrus (e.g. fusiform gyrus). V4 projects to Brodmann area 20, located in the inferior temporal 
gyrus, to Brodmann area 38, located in the anterior temporal pole, and to the limbic system. The dorsal pathway (V3 and 
V5) conveys visual information to the posterior parietal cortex (Brodmann area 7) and the premotor cortex (Brodmann 
area 6). In general, the ventral pathway in the temporal-occipital region is involved in object recognition and color 
processing, whereas the dorsal pathway processes depth and movement perception. Numbers in each cortical region 
depict corresponding Brodmann areas. 
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The primary visual cortex (also known as V1, striate cortex or Brodmann area 17) is located around 
the edges of the calcarine fissures on the medial and dorsolateral surface of the occipital lobe.3,6 The 
visual association areas (also known as the extra-striate cortices) are responsible for the 
interpretation of the visual input, such as color discrimination, motion perception, depth, and 
contrast. 3 The secondary visual cortex (V2 or Brodmann area 18) processes basic visual 
characteristics such as color perception and orientation.2,7 On the medial occipital lobe surface, V2 is 
located in the cuneus above V1 and in the medial occipito-temporal gyrus (e.g. lingual gyrus) below 
V1, whereas on the lateral surface, V2 is located in the occipital gyrus anterior to V1.2 From V2 
onwards, visual processing proceeds along two parallel pathways, the ventral (occipito-temporal) 
pathway, and the dorsal (occipito-parietal) pathway.8 The ventral stream is also known as the ‘what’ 
visual pathway, and is involved in the recognition of objects, faces and shapes and color 
processing.2,7 The dorsal stream is known as the ‘where’ visual pathway and it is suggested that this 
area is necessary for depth (three-dimensional vision) and movement perception in relation to 
objects in space in the frontal eye fields.1,2,9,10 A summary of the visual cortical areas and their 
function is presented in Table 1 and Figure 1. 
 
Table 1 Visual cortex and higher visual function 










19 (medial) / 37 
20 
Fusiform gyrus 
Inferior temporal gyrus 
Ventral ‘what’ pathway:  
Object recognition 
V3 19 Lateral part of cuneus 
Dorsal ‘where’ pathway:  
Movement and spatial perception V5 19 (lateral) / 7 
Superior occipital gyrus 
Posterior parietal cortex 
 
Any alteration in the visual pathway may result in clinical visual deficits and changes in cognitive 
performance. In Huntington’s disease (HD), a hereditary neurodegenerative disorder, cortical 
degeneration of visual brain regions is suggested to be present in early disease stages, in addition to 
striatal atrophy.11–13 HD is autosomal dominantly inherited and caused by a cytosine-adenine-
guanine (CAG) repeat mutation of the Huntingtin (HTT) gene on chromosome 4.14 The estimated 
prevalence of the disease is 5-10 per 100.000 in the Caucasian population.15 The manifest phase of 
the disease is generally characterized by progressive motor disturbances, cognitive decline, and 
behavioral changes.15 However, clinical signs can vary considerably among patients during the 
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course of the disease as well as time of disease onset. Typically, the mean age of disease onset is 
between 30 and 50 years (range from 2 to 85 years) and the mean disease duration is between 17 to 
20 years.15  
Most reported behavioral and psychiatric symptoms in HD include apathy, depression, irritability, 
and obsessive-compulsive behavior.16 Visual hallucinations or other psychotic symptoms are rarely 
seen in HD patients. In a study of 1,993 HD gene mutation carriers, mild psychosis was only observed 
in 2.9% of the study population and only 1.2% scored moderate to severe psychosis, but no visual 
hallucinations were reported.16 
Early cognitive deficits in HD mainly involve impairments in executive functioning, such as attention 
and planning difficulties, and cognitive inflexibility, which gradually progresses over time and 
eventually results in dementia.15,17 Executive dysfunction can already be present in the premanifest 
phase, before motor symptoms occur.17,18 Although deficits in visual acuity or visual dysfunction are 
not typical clinical features of HD, visuospatial deficits are reported in HD patients. Such visuospatial 
deficits are of clinical importance because they can influence overall cognitive performance and may 
have major functional implications, for example the impact on driving a car or using electronic 
devices such as mobile phones and computers. Also, visual deficits should be taken into account 
when conceptualizing cognitive assessments for measuring drug efficacy in clinical trials. By 
providing an overview regarding the brain structure and function of the visual cortex in patients with 
HD, we propose to provide novel information on disease progression and cortical degeneration. 
Therefore, the aim of this review is to summarize the current literature regarding visual cognitive 
impairment and identify the posterior cortical changes that occur in HD patients.  
 
2. Methods 
A review of the existing literature on visual impairment in HD was conducted using the electronic 
database of PubMed/Medline. All literature published before August 2017 was critically reviewed. 
The following search terms were used in several combinations to identify the available literature: 
“Huntington”, “Huntington’s disease”, “visual”, “visual cognition”, “visual processing”, 
“visuospatial”, “atrophy”, “occipital cortex”, “cerebral blood flow”, “visual pathway”, and “visual 
system”. In addition, potential eligible studies were also screened using the reference lists of the 
studies found. Only original research papers and review articles written in English were considered 
for further review. Animal model studies, letters to editors and editorial comments were excluded. 
Articles that examined the visual cortex and/or assessed visual cognition in manifest and 




3.1. Search results 
Of the 1,406 articles that were identified by the initial database search, 85 articles were selected for 
further review based on the abstract. Twenty-two studies were included for this review as these 
studies specifically investigated visual function in HD. Of these 22 studies, one post-mortem brain 
study and six neuroimaging studies addressed changes of the visual cortex in HD gene carriers, and 
15 neuropsychological studies assessed visual cognitive functioning in HD. We will first focus on the 
structural and functional changes of the visual cortex reported in manifest and premanifest HD gene 
carriers in paragraphs 3.2.1 and 3.2.2. An overview of the literature regarding changes of the visual 
cortex is also provided in Table 2. In paragraph 3.2.3, we will discuss the findings of studies 
investigating visual cognition in HD using the following cognitive domains: visual perception, 
visuospatial processing, visual working memory, visuoconstruction and visuomotor function. These 
visual cognitive domains and their associated neuropsychological tasks are summarized in Table 3. 
Furthermore, a summary of the current literature on visual cognition in HD is given in Table 4. 
Besides the 22 studies that investigated visual function in HD, another 26 articles were additionally 
reviewed, of which 24 articles assessing whole brain changes in HD, and two articles examining an 
extensive neuropsychological assessment battery in HD. These studies did not specifically aim to 
focus on the visual system, but did report relevant findings on the visual pathway in HD and will 
therefore be discussed in the corresponding paragraphs.  
 
3.2. The visual cortex in Huntington’s disease 
Neuropathological alterations in HD are primarily found in the striatum, especially in the caudate 
nucleus and putamen, due to loss of striatal medium-sized spiny neurons.19 Although striatal atrophy 
is considered to be the origin of choreiform movements seen in HD patients, it is suggested that 
other symptoms of HD are related to cortical degeneration, as extensive neuronal loss is seen 
throughout the cerebral cortex when the disease progresses.20–22  
 
3.2.1. Structure of the cerebral cortex 
A post-mortem brain study showed a 32% reduction of nerve cells in the primary visual area 
(Brodmann area 17) in brains of 7 HD patients in advanced disease stages compared to 7 controls.23 
The authors conclude that damage to the primary visual area contributes to the pathogenesis of 
visual dysfunction.23 This study, however, only examined nerve cells in Brodmann area 17 in the 
occipital lobe and did not assess other brain regions, which is contrary to another study that 
examined the patterns of neuronal cell loss in the frontal, parietal, temporal, and occipital lobes in 
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post-mortem brains of 14 end stage HD patients.21 Compared to controls, HD patients showed the 
highest difference in pyramidal neuron cells in the secondary visual cortex (42% decrease), whereas 
no significant pyramidal cell differences was observed in the primary visual cortex (3% decrease).21 
In comparison, a 27-34% reduction in pyramidal cell number was found in HD patients compared to 
controls for the superior frontal, middle temporal, superior parietal, and primary sensory cortices.21 
Between HD patients, there was additionally more neuronal loss in the secondary visual cortex (36% 
loss) than in the primary visual cortex (12% loss), suggesting that mainly associative visual regions 
are impaired in HD.21 These latter findings were confirmed by a MRI study that observed reduced 
cortical thickness of the lingual gyrus and lateral occipital cortex in premanifest gene carriers close to 
disease onset (n=58) and early stage HD patients (n=40) that was associated with worse visuospatial 
task and visual working memory performance measured with the Map Search task, Spot the change 
task and the Trail Making Test part A.13 No associations were found between cognitive performance 
and thickness of the cuneus. This implies a distinct association between higher-level cognitive 
performance and cortical occipital degeneration.13 An additional MRI study examined structural 
posterior brain changes in relation to visuospatial attention in premanifest (n=119) and early stage 
manifest HD (n=104), and found associations between poorer visuospatial performance (measured 
using the Map Search and mental rotation tasks) and volume loss in the cuneus, lingual, fusiform 
gyri, and motor regions in manifest HD compared to controls.24 Another study focused on the link 
between visuomotor performance and prefrontal cortex atrophy, but additionally found focal 
volume loss in the occipital cortex and associations between this volume loss and poorer visuomotor 
performance (measured using the 15-Object test, a visuomotor integration task).25 Yet, another 
study examining visuomotor function using the Circle Tracing task and cortical volume loss did not 
find any significant association between visuomotor task performance and the visual and motor 
cortices,26 but this might be explained by the fact that in these studies different cognitive 
assessments were used to evaluate visuomotor function. 
In studies focusing on whole brain cortical changes and associations with clinical impairments, 
reduced cortical thickness of the cuneus,12,27 and volume loss of the occipital lobe,11,28–31 and parietal 
lobe 12 were observed in both premanifest and early manifest disease stages compared to controls. 
In conclusion, volumetric changes of posterior cortical regions can already be detected in early 
stages of the disease, even in the premanifest phase, while frontal and temporal regions remain 





3.2.2. Cortical brain function 
It is thought that clinical manifestations of HD not only depend on brain atrophy, but are also 
influenced by neuronal dysfunction and loss in neuronal network structure.32  
Functional MRI (fMRI) can be used to study neural function. Several fMRI studies in HD gene carriers 
showed changes in multiple functional brain networks before brain atrophy or clinical symptoms 
were present.32,33 
Only one functional imaging study focused on the visual system in 20 early HD patients using resting-
state fMRI.34 Resting-state fMRI assesses overall brain connectivity that is not related to task 
performance. Reduced fusiform cortex activity in HD patients was found after correcting for whole 
brain atrophy compared to controls.34 The authors therefore conclude that activation differences in 
the occipital cortex could not sufficiently be explained by regional brain volume loss alone. Another 
study reported reduced brain connectivity using whole brain resting-state fMRI in the occipital 
cortices in both premanifest and manifest HD gene carriers compared to controls.35 However, 
decline in brain connectivity over time in the occipital region was not confirmed in longitudinal 
resting-state fMRI studies.36,37 
It is suggested that visual stimulation results in an increase in glucose uptake in the brain and 
cerebral blood flow.38 Therefore, a 31phosphorus nuclear magnetic resonance (NMR) spectroscopy 
study used a basic visual stimulation task to activate the occipital cortex and measure metabolite 
concentrations for the assessment of brain energy deficits in manifest HD (n=15) compared to 
controls (n=15).39 An increase in metabolite concentrations was observed in controls, whereas HD 
patients did not show any response to brain activation, indicating impaired mitochondrial function in 
the visual cortex.39 In addition, two small task-based fMRI studies demonstrated reduced neural 
activity of the occipital cortex, during a Porteus Maze task in 3 premanifest individuals,40 and during 
a serial reaction time task in early and premanifest HD patients (n=8).41  
These studies also showed reduced activation in the caudate, parietal and sensorimotor cortices,40 
and in the middle frontal gyri and precuneus.41 As these tasks were examined in small patient groups 
and involve a combination of basic and higher visual processing, motor speed, and spatial 





Table 2 Overview of current literature on the visual cortex in HD 
 
 Study population Clinical HD disease stage Study design Assessments Main significant finding 
Gomez-
Anson et al., 
2009 25 
Controls n = 21 
PreHD n = 20 
YTO: not available 
PreHD1: n = 12 (UHDRS-TMS = 0) 
PreHD2: n = 8 (UHDRS-TMS = 8) 
Structural MRI 15-Objects test  Volume loss in cerebellum, prefrontal 
and posterior temporal cortices. 
Correlation with visuomotor task 
performance and prefrontal and occipital 
cortices. 
Say et al., 
2011 26 
Controls n = 122 
PreHD n =119 
HD n = 120 
PreHD-A n = 62, YTO: 14.1 years 
PreHD-B n = 57, YTO: 8.7 years 
HD1 n = 75 
HD2 n = 45  
Disease duration: not available 
Structural MRI 
(TRACK-HD) 
Circle tracing task 
(direct and indirect) 
No associations of task performance and 
loss of volume in visual and motor 
cortices. Only slower performance of 
indirect task was associated with lower 
grey mater volume in somatosensory 
cortex. 
Mochel et 
al., 2012 39 
Controls n = 15 
HD n = 15 
HD1 n = 15 





Unchanged metabolic concentrations 
during and after visual stimulation in HD. 
Wolf et al., 
2014 34 
Controls n = 20 
HD n = 20 
HD1/2 n = 20 
Disease duration: 3.2 years 
Resting-state fMRI  SDMT 
VOSP 
Decreased activity of left fusiform cortex, 
associated with lower scores on SDMT 
and higher disease burden in HD. 
Johnson et 
al., 2015 13 
Controls n = 97 
PreHD n = 109 
HD n = 69 
PreHD-A n = 51, YTO > 10.8 years 
PreHD-B n = 58, YTO < 10.8 years 
HD1 n = 40 
HD2 n = 29  
Disease duration: not available 
Structural MRI  
(TRACK-HD) 
SDMT 




Spot the change 
Reduced occipital cortical thickness in 
preHD and HD patients. Except for 
mental rotation, poor performance on all 
cognitive tests was associated with 
thinner cortex for lingual and lateral 
occipital cortices in HD. 
Rüb et al., 
2015 23 
Controls n = 7 
HD n =7 
Age at death: 52.43 years 
Age at disease onset: 40.57 years 




N/A A 32% reduction of estimated absolute 
nerve cell number in Brodmann area 17 
in HD patients compared to controls. 
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Labuschagne 
et al., 2016 24 
Controls n = 110 
PreHD n = 119 
HD n = 104 
PreHD-A n = 55, YTO > 10.8 years 
PreHD-B n = 64, YTO < 10.8 years 
HD1 n = 59 
HD2 n = 45 
Disease duration: not available 




Cognitive performance was associated 
with parieto-occipital (cuneus, calcarine, 
lingual) and temporal (posterior 
fusiform) volume and thickness in HD 
gene carriers.  
Clinical stages of the study population are provided in the table, if information was available in the original papers. PreHD-A and PreHD-B indicate premanifest HD gene carriers classified 
based on the estimated time to disease onset (far or close respectively). Manifest HD gene carriers can be divided into HD stages based on their functional capacity, in which HD1 and HD2 
represent early disease stages, and HD5 the most advanced stage.  
Abbreviations: PreHD = premanifest HD gene carriers, HD = manifest Huntington’s Disease, YTO = estimated years to disease onset, MRI = Magnetic Resonance Imaging, NMR = nuclear 
magnetic spectroscopy, UHDRS-TMS = Unified Huntington’s Disease Rating Scale – Total Motor Score, SDMT = Symbol Digit Modality Test, VOSP = Visual Object and Space Perception, TMT = 
Trail Making Test, N/A = Not Applicable 
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3.2.3. Cerebral metabolism 
With positron emission tomography (PET) imaging, functional or metabolic changes in HD can be 
studied using a radioactive labeled tracer that binds to specific structures within the brain. Several 
reviews have recently discussed the developments of PET imaging in HD.42–44 Overall, there is 
increasing evidence of reduced glucose metabolism in the striatum, and frontal and temporal 
cortices, which seem to be reliable predictors of disease progression in HD.42–44 There have been no 
PET studies performed to date that specifically focused on the glucose metabolism of the visual 
cortex in HD patients. However, an interesting finding was observed by a study group that examined 
spatial covariance patterns between different networks of regions with altered glucose metabolism 
using PET imaging.45,46 A relative increase in glucose metabolism was found in thalamic, motor, 
occipital and cerebellar regions, in association with a decrease in striatal metabolism in HD patients 
compared to healthy controls.45,46 A recent study reports similar findings of striatal hypometabolism 
in combination with hypermetabolism in the cerebellum, thalamus, and occipital cortex.47 Here, 
hypermetabolism in the cuneus and lingual gyrus was negatively correlated with hypokinetic motor 
scores. These findings suggest that a decrease in glucose metabolism might be linked to clinical 
disease onset, whereas an increase in glucose metabolism indicates a compensatory mechanism for 
neuronal loss and/or motor disturbances.46,47 As neuronal loss is indirectly measured using 
functional MRI, the reduced brain activity in the occipital cortex of HD patients found in previous 
fMRI studies might indeed explain the hypermetabolism found in these PET studies.  
Another approach to assess alterations in metabolism is by measuring cerebral blood flow (CBF) or 
cerebral blood volume (CBV) using transcranial Doppler (TCD) ultrasonography, PET imaging or 
arterial spin labeling MRI.48 
Reductions in cerebral blood flow and elevations in cerebral blood volume were primarily observed 
in frontal cortical regions in premanifest HD gene carriers.49,50 In manifest HD, hypoperfusion was 
additionally observed in the fronto-parietal regions and anterior cingulate cortex during a word 
generation task,51 motor task,52 and executive functioning tasks,53,54 but no alterations in cerebral 
perfusion were detected in the posterior cortex during task performance. One study reported 
heterogeneous regional CBF reductions in rest in 17 early manifest HD extending to the 
sensorimotor, paracentral, inferior temporal and lateral occipital regions, with normal CBF in the 
thalamus, postcentral gyrus, insula, and medial occipital areas.55 However, the degree of cortical 
thinning exceeded CBF reductions in the temporal and occipital cortices, and in the striatum, 
suggesting that structural and vascular alterations might originate from different underlying 
pathologic mechanisms.55 More studies are necessary to evaluate the manner of perfusion changes 
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over the course of the disease but hypoperfusion seems to play a role in the pathophysiology of 
neuronal dysfunction in HD.    
In conclusion, although the visual system has not been the main focus in many imaging studies in HD 
to date, atrophy (i.e. volume loss and cortical thinning), reduced neural activity and functional 
connectivity, and changes in glucose metabolism of the posterior cerebral cortex have been 
reported in both early stage HD patients and premanifest gene carriers. This suggests that the 
posterior cerebral cortex might be one of the first cortical regions to undergo pathological and 
functional changes.  
 
3.3. Visual cognition in Huntington’s disease 
Many studies investigated the progression of cognitive impairment in different HD disease stages.17 
Here, we will focus on studies assessing cognitive deficits in HD that involve a visual component. 
Visual cognitive functioning can be divided into different domains of visual processing, however, the 
terminology that is used to define visual cognition widely differs among the current literature. Also, 
many neuropsychological assessments that are used to evaluate visual cognitive function often 
require a combination of several domains, such as visual attention, spatial orientation and working 
memory. Additionally, in HD patients, possible influence of a motor component on cognitive 
performances should also be considered. Below, we will discuss the reviewed studies using the 
following domains: visual perception, visuospatial processing, visual working memory, 
visuoconstruction and visuomotor function (Table 3). 
In general, color, patterns, depth, motion perception, and the recognition of facial expressions of 
emotions are usually classified as visual perceptual skills. Visuospatial processing or visual scanning 
and attention are needed to visually perceive objects and assess the spatial distance and 
relationship among items or objects. Visual working memory accounts for the recall of visuospatial 
stimuli. Visuoconstruction is defined as the ability to organize and manually manipulate spatial 
information to make a design, i.e. copying a complex figure or constructing three-dimensional 
figures from two-dimensional units.56 Last, visuomotor function involves visual scanning and tracking 
of movement and the ability to maintain gaze on a moving target.57  




Table 3  Visual cognitive domains and associated neuropsychological assessments 
 
Domain Definition Assessments 
Visual perception 
Color perception Perception of colors and ability to 
distinguish contrast 
Ishihara Color Test, Contrast Sensitivity 
Test 
Visual recognition Recognition of faces and facial 
expression of emotions 
Emotion Recognition Tasks 
Visual organization  Perceptual reorganizing to 
distinguish incomplete fragmented 
visual stimuli 
Closure Speed, Visual Object and Space 
Perception battery, Hooper Visual 
Organization Test 
Visuospatial function 
Visual attention Awareness of visual stimuli Line Bisection Test, Cancellation Task, 
Visual Search and Attention Test, 
Embedded Figures, Map Search, Trail 
Making Test A 
Visual scanning Ability to acquire information 
regarding environment and spatial 
distance (e.g. for reading, writing, 
telling time) 
Counting dots, Visual Scanning Test, 
Mental Rotation, Street Map Task, 
Symbol Digit Modalities Test, Digit 
Symbol Task 
Visual working memory 
Visual recognition memory Ability to retrieve visuospatial 
information from memory 
Recurring Figures Test, Family Pictures 
(subtest of Wechsler Memory Scale-III), 
Trail Making Test B 
Visual Recall Reproduction of a design or object Visual Reproduction Task (immediate 
and delayed recall), Spot the change 
Task 
Visuospatial Learning Learning and recall memory of 
visuospatial stimuli 
Visuospatial Learning Test, Trail 
Learning Test 
Visuoconstruction  
Visuoconstructive ability Spatial ability to reproduce complex 
geometric designs 
Rey-Osterrieth Complex Figure Test 
Visuomotor function 
Visuomotor  Ability to maintain gaze on a moving 
target 
Circle-Tracing Task (direct and indirect 
feedback), 15-Objects task 
Based on Lezak et al., 2004 56 
 
 
3.3.1. Visual perception  
The perception of colors, contrast, and motion, the recognition of objects, facial expression, and 
emotions, and conceptual organizing skills are all classified as visual perception. The lateral 
geniculate nucleus is involved in the processing of colors and contrast resolution before further 
functional differentiation occurs in the striate cortex.58 Limited studies have been performed that 
address basic visual processing of contrast and motion in HD. Patients with HD showed impaired 
contrast sensitivity for moving stimuli,59 while contrast sensitivity for static stimuli seems unaffected 
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in HD patients.59,60 This might indicate involvement of the (pre)-striate visual cortex early in the 
disease process.59 Still, no structural or functional neuroimaging studies have been performed that 
confirm this hypothesis.  
Conceptual organization or visual object perception has been examined in several studies in 
patients with HD, but methods differ and findings are inconsistent. One study assessed 
visuoperceptive function using the Hooper Visual Organization test in premanifest and manifest HD 
gene carriers, for which participants needed to recognize and name the object that is displayed on a 
card in fragmented form.61 Both early and more advanced HD patients scored significantly lower on 
this task compared to premanifest and control individuals. No differences in scores were observed 
between premanifest HD and controls. Remarkably, 70% of the premanifest individuals scored 
above 25 points (maximum of 30 points), while only 20% of the early manifest individuals reached 
this score, which illustrates the impaired task performance in manifest HD.61  
Three other studies assessed visuoperceptional skills in HD patients using the Visual Object and 
Space Perception (VOSP) battery, which measures object recognition and space perception 
separately in eight subtests with minimal involvement of motor skills and executive 
functioning.34,62,63 A cross-sectional study showed that out of all the subtests of the VOSP, only the 
performance on the object decision task was impaired in HD patients (39% of the HD patients 
performed below the fifth percentile of the control norm),63 while another cross-sectional study 
found an overall worse performance on the silhouettes and object decision subtasks in early HD 
patients compared to controls.34 Brain activity of the fusiform gyrus did not predict the performance 
on visual object perceptional tests,34 which is unexpected since the fusiform gyrus is thought to be 
involved in object and facial recognition.64 A longitudinal study that assessed in addition to visual 
cognition also executive function, language, learning, and intelligence, reported a decline in 
performance for object recognition and space perception in HD patients after a follow-up period of 
2.5 years, measured using sum scores for all object recognition tasks and space perception tasks.62  
In contrast, a small study in 10 HD patients reported that the identification of individual objects and 
objects adjacent to each other remained unaffected, while deficits were found in the simultaneous 
perception of multiple objects that were presented in an overlapping manner.65  
 The perception of motion can be measured using a motion discrimination task, in which 
participants need to decide whether dots moved to the right or left in a field of noise. Here, findings 
are also inconsistent, when assessing a motion discrimination task in HD patients.59,60 In a pilot study 
of 8 HD patients and 9 premanifest HD gene carriers, the discrimination of motion trajectories in 
noise was impaired in the manifest HD group, but not in premanifest HD gene carriers.60 In a 
subsequent study with a larger sample (201 controls, 52 premanifest and 36 manifest HD gene 
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carriers), no differences were observed in the performance on this task among different HD gene 
carrier groups and controls.59 The authors explained these different findings because of possible 
differences in the severity of HD participants that were included in the two studies.59 Therefore, no 
conclusions can be drawn from this limited evidence on the motion perception performance in HD 
patients.  
In contrast, visuoperceptual recognition of facial expressions and emotions has been 
extensively studied in HD patients. Several reviews have recently evaluated the current literature on 
emotion recognition in HD.66–68 Briefly, the ability to recognize basic emotions from facial 
expressions has consistently been found to be impaired in both manifest and premanifest HD, 
especially for negative emotions such as anger, disgust, and fear.67,68 Impairments in facial emotion 
recognition in HD seem to be associated with regional loss of brain tissue, altered brain activation, 
and changes in brain connectivity.68 A large study by the Predict-HD study group found that, in 
premanifest HD gene carriers, deficits in negative emotion recognition were associated with atrophy 
of the fronto-striatal network, the precuneus and occipital regions, such as the lingual gyrus, cuneus, 
lateral occipital cortex, and middle-temporal cortex.69 
 
3.3.2. Visuospatial function 
The dorsal temporo-occipital pathway is suggested to be involved in visuospatial cognition.1 
Visuospatial attention involves the awareness of visual stimuli to perceive objects, while visuospatial 
scanning is necessary to acquire information regarding the environment, spatial distance and 
relationship among objects. Therefore, visuospatial processing is important for daily functioning, 
such as walking, driving, reading, and writing, and is often essential when measuring other cognitive 
domains.  
Eight studies specifically investigated visuospatial function, visual attention or visual scanning in HD 
patients.13,24,34,61,70–73 One study assessed a wide range of visuospatial tasks in HD patients and 
controls.70 Factor analyses showed that overall visuospatial processing capacity (measured using the 
performance subscales of the WAIS-R, Embedded Figures Test, and Mental Reorientation Test) and 
spatial manipulation (involving performance on the Mental Rotation and Street Map task) were 
impaired in HD, whereas spatial judgment (comprising of scores of the Rod-And-Frame Test and In-
Front-Of Test) appeared unaffected.70 
Another study also examined the ability to spatially rotate a mental image (i.e. a mental rotation 
task) in patients with HD and patients with Alzheimer’s disease (AD).71 HD patients were able to 
mentally rotate a figure through space, but showed slowing in information processing speed (i.e. 
bradyphrenia) resulting in a worse performance, whereas in AD patients the accuracy, not the 
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speed, was impaired compared to their respective age-matched controls 71 Other more recent 
studies, however, reported worse performance on the Mental Rotation task in both premanifest and 
manifest HD gene carriers compared to controls, with poorer performance in the more advanced 
disease stages that was not influenced by bradyphrenia.13,24  
Different neuropsychological assessments were used to measure visual scanning and attentional 
deficits in HD patients in several studies.24,34,61,72,73 The Cancelation Task and Line Bisection Test did 
not show any differences in visual attentional function between healthy controls, premanifest, and 
manifest HD gene carriers.61 In a longitudinal study, decline in performance on the Map Search 
attentional task was only observed in more advanced HD patients after a 12 months follow-up 
period.24  
The Symbol Digit Modalities Test (SDMT) and the Trail Making Test (TMT) are widely used 
assessments to measure cognitive function in HD patients.62,74,75 The SDMT is found to be the most 
sensitive cognitive task in large longitudinal studies to detect progressive change in HD gene 
carriers.62,74,75 An explanation for this might be that the SDMT is a demanding task that requires a 
high degree of visual scanning and memory, processing speed, object recognition, oculomotor 
function and motor speed. One study assessed the association between cognitive task performance 
and visual brain activity changes.34 Here, early HD patients’ lower fusiform activity was associated 
with worse performance on the SDMT, which is not surprising as the SDMT also involves the 
recognition of symbols and shapes.34 
Among a large group of 767 premanifest HD gene carriers, the TMT part A was associated with visual 
search and sustained attention, whereas TMT part B was associated with executive functioning, 
processing speed and working memory.72 Premanifest HD gene carriers close to disease onset 
performed worse on both TMT part A and part B. Interestingly, only part A scores seemed to be 
mildly affected by motor disturbances.72 
Only one study specifically assessed visual scanning in premanifest and manifest HD gene carriers 
using the Digit Symbol Subtest, a subscale of the Wechsler Adult Intelligence Scale - Revised (WAIS-
R), and quantitative eye movements.73 While all participants used a similar visual scanning strategy, 
slowing and irregular visual scanning in both premanifest and manifest HD was related to worse 
performance on the Digit Symbol task compared to controls.73 Although this might suggest deficits in 
visual scanning in early disease stages, the influence of motor impairment on cognitive performance 
was not taken into account.  
Overall, visuospatial function in HD patients has been examined using various cognitive batteries, 
making it difficult to directly compare study findings. Some visual attentional tasks (such as the 
Mental Rotation, TMT part A and the SDMT) revealed impaired performance in both premanifest 
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and manifest HD, while other tasks (such as the Line Bisection Test and Cancellation Task) showed 
no differences in task performance. 
 
3.3.3. Visual working memory  
Visual working memory accounts for the ability to retrieve visuospatial information from memory, 
and involves learning and recall of visuospatial stimuli. Six studies assessed visuospatial memory 
function in HD patients.13,63,76–79  
Compared with other neurodegenerative disorders, such as Alzheimer’s’ disease (AD) and 
Parkinson’s disease (PD), patients with HD showed impairments in spatial working memory and 
visuospatial learning.76,77 In these studies, visuospatial working memory was determined as the 
ability to recall a sequence of squares at the right location on a screen76, the recognition of abstract 
visual stimuli76, and the recall of the right naming and location of sketched objects on cards.77 
Patients with HD were better at correctly naming the objects than recalling their spatial location, 
whereas the opposite was true for the AD and PD patients.77 This was confirmed by a study in early 
stage HD patients that measured visual object and visuospatial working memory using an extensive 
battery of cognitive visual assessments.63 Here, deficits in pattern and spatial recognition memory, 
decreased reaction times in visual search, and an impaired spatial working memory were found in 
HD patients, while visual object working memory showed no changes compared with healthy 
controls.  
To evaluate the influence of slowness of execution (bradykinesia), thinking (bradyphrenia) or motor 
speed on visual memory task performance, one study assessed accuracy and reaction times between 
different disease stages on a visual comparison task to spot the change of randomly selected colors 
between images.78 Premanifest HD gene carriers close to disease onset and early stage HD patients 
showed lower working memory accuracy and slower response times compared to controls. As 
premanifest individuals without motor signs also showed impairments in task performance, the 
findings of this study imply that results are influenced by a decrease in cognitive performance and 
impaired information processing, rather than reduced motor speed.78 
A more recent study also reported poorer performance on the ‘Spot the change’ task in more 
advanced disease stages.13 In addition, task performance was associated with thickness of the lateral 
occipital cortex and lingual gyrus, while a non-visual motor task showed no associations with the 
visual cortex.13 This implies that the changes in occipital thickness are specific to visual cognition 
rather than general disease progression.13 In another study, visuospatial memory function was 
evaluated in HD patients and healthy controls using the Visual Spatial Learning Test (VSLT), which is 
a nonverbal memory test that measures immediate and delayed memory for designs and locations 
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without requiring motor or language skills.79 Compared to controls, premanifest HD gene carriers 
showed, besides an impaired recall for associations between object and spatial location, no deficits 
in the memory for objects, while HD patients showed impairments on all measures.79 
Generally, retrieving visuospatial information from memory seems to be inaccurate in early manifest 
stages and even in premanifest HD gene carriers close to disease onset, whereas the recognition and 
recall of naming objects from memory appears to be less affected. 
  
3.3.4. Visuoconstructive abilities 
Visuoconstruction involves the spatial ability to reproduce complex geometric designs. 
Interpretation of visuoconstructive deficits can be difficult because tests that are used to measure 
visuoconstruction often involve other domains, such as visuospatial, executive and motor 
functioning. Only two studies investigated visuoconstructive skills in HD patients by assessing the 
ability to copy a complex figure using the Rey-Osterrieth Complex Figure Test.61,80 The first study 
explored these visuoconstructive abilities of HD patients with age-matched controls for HD by 
recording the accuracy and time to copy the design.80 Here, patients with HD showed no differences 
in accuracy but needed more time to complete the test compared to their matched control group, 
which may have been due to the presence of motor disturbances.80 A second study examined the 
same part of the Rey-Osterrieth Complex Figure test, in premanifest and manifest HD gene carriers 
but measured the correct elements that were copied instead of evaluating the accuracy of the lines 
to minimize motor interference.61 In HD patients, total correct scores declined in more advanced 
disease stages. Furthermore, early HD patients showed mild deficits in visuoconstruction but this 
was not significant compared with premanifest HD gene carriers.  
Based on this literature, visuoconstructive skills become impaired in the more advanced disease 
stages. Still, more studies are necessary to fully determine the extent of these impairments and the 
possible influence of motor signs and bradyphrenia.  
 
3.3.5. Visuomotor function 
Visuomotor deficits in the tracking of movements and the ability to maintain gaze on a moving 
target have been reported in HD patients.25,26,81,82 
In two studies using a circle-tracing task to measure indirect and direct visual feedback, early HD 
patients were slower, less accurate and needed more time to detect errors.26,82 This is consistent 
with another study using a visual tracking task that showed a higher error rate and longer time 
scores in HD patients, especially in the non-dominant hand, compared to controls.81 Premanifest HD 
gene carriers also showed less accuracy in completing the task compared to controls, however, no 
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associations were found between visuomotor integration deficits in HD gene carriers and volumes of 
visual and motor cortices.26 This might be explained by the multifactorial demands of the circle-
tracing task that was used as an outcome measure.  
To the contrary, another study found correlations between impaired visuomotor performance in 
premanifest HD gene carriers and decreased volumes of the prefrontal and occipital cortices.25 In 
this study, visuomotor integration performance was measured using the time to complete the 15-
objects test that contains 2 figures, each with overlapping drawings of 15 different items.25 This task, 
however, can also be used to assess visual perception and in addition, it remains uncertain if other 
signs of HD, such as bradyphrenia, motor and eye movement disturbances, or visuoperceptional 




Table 4 Overview of current literature on visual cognition in HD 
 Study population Clinical HD disease stage Domain Assessments Main significant finding 
Brouwer et al., 1984 
80 
Controls n = 25 * 
HD n = 10  
AD n = 14 




Road Map Test 
Rey-Osterrieth Complex 
Figures 
Mosaic Comparisons Test 
Stylus Maze Test 
Impairments in visual 
discrimination, no difference in 
visuoconstructive ability and 
route learning in HD compared 
to controls 
Oepen et al., 1985 81 Controls n = 63 
HD n = 15 
HD at risk n = 17 
YTO: not available (before genetic 
testing) 
Disease duration: not available 
Visuomotor function Continuous and 
discontinuous 
drawing/tracking task 
Significant higher error rate 
(less accuracy) and longer time 
scores in HD compared to 
controls, especially in non-
dominant hand 
Mohr et al., 1991 70 Controls n = 19 
HD n = 20 
Disease duration: 6 years Visuospatial 
function 
Performance subtests of 
WAIS-R 
Embedded Figures Test 
Rod-and-Frame Test 
Mental Rotation Test 





processing capacity and spatial 
manipulation in HD, no 
impairments in spatial judgment 
(Rod-and-Frame test and In-
Front-Of Test) in HD compared 
to controls 
Lange et al., 1995 76 Controls n = 85 * 
AD n = 13 
HD n =10 
Disease duration: not available Visuospatial learning 
and memory 
Pattern and Spatial 
Recognition Test 
Matching-to-Sample test 
Worse performance on spatial 
pattern recognition task and  
Spatial recognition of abstract 
stimuli 
Gomez-Tortosa et 
al., 1996 61 
Controls n = 11 
PreHD n = 15 
HD n = 35 
YTO: not available 
Disease duration: not available 
HD1 n = 13 
HD2 n = 9 










Impaired visuoperception in HD 
patients, no significant 
differences between preHD and 
controls 
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Lawrence et al., 
2000 63 
HD-a n = 19 vs. 
Controls-a n = 20 
 
HD-b n = 19 vs. 
Controls-b n = 20 
 
HD-c n = 21 vs. 
Controls-c n = 17 
Age at onset: 42.5 years 
Disease duration: 5 years 
Visual object and 
visuospatial memory 
HD-a: DMTS, VSMTS, 
VOSP 
HD-b: PAL 
HD- c: Pattern and Spatial 
recognition test, spatial 
working memory task 
Deficits in pattern and spatial 
recognition memory, reaction 
times in visual search, and 
spatial working memory 
O’Donnell et al., 
2003 60 
Controls n = 20 
PreHD n = 9 
HD n = 8 
YTO: not available 
Disease duration: 1 – 2 years 
Early stage visual 
processing 
Digit Symbol test 
Contrast sensitivity 
Motion discrimination 
Impaired motion discrimination 
in HD, not in preHD  
Brandt et al., 2005 77 Controls n = 147 
AD n = 143 
PD n = 77 
HD n = 110 
Disease duration: 7.7 years Visuospatial object 
and location 
memory 
‘Hopkins Board’ (object 
identity and recall of 
spatial locations) 
Impaired delayed recall of 
spatial location of items in HD 
compared to AD and PD 
Lemay et al., 2005 82 Controls n – 13 
HD n = 13 
Disease duration: 0.5 – 6 years Visuomotor function Circle tracing task (direct 
and indirect) 
Early HD patients were slower 
and deviated more than 
controls for the indirect visual 
feedback task. No differences in 
direct visual feedback 
Lineweaver et al., 
2005 71 
Controls n = 40 * 
AD n = 18 
HD n = 18 
Disease duration: not available Visuospatial 
function 
Mental Rotation task  Decreased speed in mental 
rotation task in HD and reduced 
accuracy in AD, compared to 
controls 
Finke et al., 2007 65 Controls n = 15 
HD n = 10 
Age at onset: 37.4 years 





Simultaneous perception of 
multiple object in overlapping 
manner was impaired in HD, 
identification of single objects 
or objects adjacent to each 
other was unaffected in HD 
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Blekher et al., 2009 
73 
Controls n = 23 
PreHD n = 21 
HD n = 19 
YTO: not available 
Disease duration: not available 
Visual scanning Digit Symbol test 
Visual scanning using eye 
movements 
Slow and irregular visual 
scanning related to worse 
cognitive performance in preHD 
and HD  
Gomez-Anson et al., 
2009 25 
Controls n = 21 
PreHD n = 22 
YTO: not available 
PreHD1: n = 12 (UHDRS-TMS = 0) 
PreHD2: n = 8 (UHDRS-TMS = 8) 
Visuomotor function 15-Objects test 
Stroop 
TMT A and B 
Digit Symbol test 
Rey’s Complex Figure 
Benton’s Line Orientation 
test  
PreHD performed slower on the 
15-Objects test than controls. In 
total, 13 preHD (59%) had 
impaired performance in at 
least one of the other 
assessments 
O’Rourke et al., 
2011 72 
Controls = 217 
PreHD = 767 
PreHD Far n = 297, YTO > 15 years 
PreHD Mid n = 287, YTO: 9 – 15 
years 





TMT part A 
TMT part B 
In preHD, TMT part A measures 
visual search and sustained 
attention, TMT part B measures 
cognitive flexibility and working 
memory 
Say et al., 2011 26 Controls n = 122 
PreHD-A n = 62 
PreHD-B n = 57 
HD1 n = 75 
HD2 n = 45 
PreHD-A n = 62, YTO: 14.1 years 
PreHD-B n = 57, YTO: 8.7 years 
HD1 n = 75 
HD2 n = 45  
Disease duration: not available 
Visuomotor function Circle tracing task (direct 
and indirect) 
Less accuracy and slower task 
performance in both circle-
tracing conditions for early and 
preHD. With indirect condition, 
early and preHD required longer 
to detect and correct errors 
compared to controls 
Dumas et al., 2012 78 Controls n = 122 
PreHD n = 120 
HD n = 121 
PreHD-A n = 62, YTO: 14 years 
PreHD-B n =58, YTO 9 years 
HD1 n = 77, disease duration: 5 
years 




Spot the change  Slow response times in preHD 
close to disease onset and early 
manifest HD  
Wolf et al., 2014 34 
 
Controls n = 20 
HD n = 20 
HD1/2 n = 20 
Disease duration: 3.2 years 
Visual scanning and 
visual object 
SDMT 
VOSP - subtests for object 
Decreased performance on all 
tasks in HD, lower fusiform 
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 function function activity only associated with 
worse performance on SDMT in 
HD 




Controls n = 97 
PreHD n = 109 
HD n = 69 
PreHD-A n = 51, YTO > 10.8 years 
PreHD-B n = 58, YTO < 10.8 years 
HD1 n = 40 
HD2 n = 29  







Stroop Word Reading 
Trail Making Task part A 
Map Search 
Mental Rotation 
Spot the Change 
Worse performance on all tasks 
in advanced HD. Except for 
Mental Rotation, relation 
between task performance and 
occipital thickness in HD, see 
also Table 2 
Pirogovsky et al., 
2015 79 
Controls n = 31 
PreHD n = 30 
HD n =19 
YTO: not available 
Age at onset HD: 44.7 years 
Disease duration: not available 
Visuospatial 
memory 
VLST Impaired recall and recognition 
of designs in HD, object-place 
association memory impaired in 
preHD  




Controls n = 110 
PreHD n = 119 
HD n = 104 
PreHD-A n = 55, YTO > 10.8 years 
PreHD-B n = 64, YTO < 10.8 years 
HD1 n = 59 
HD2 n = 45 




Map Search  
Mental rotation  
Lower scores on Map Search 
and Mental rotation task in all 
groups compared to controls. At 
follow-up, only declined 
performance in HD 
* Controls were age-matched for AD and HD separately 
Clinical stages of the study population are provided in the table, if information was available in the original papers. PreHD-A and PreHD-B indicate premanifest HD gene carriers classified 
based on the estimated time to disease onset (far or close respectively). Manifest HD gene carriers can be divided into HD stages based on their functional capacity, in which HD1 and HD2 
represent early disease stages, and HD5 the most advanced stage.  
Abbreviations: PreHD = premanifest HD gene carriers, HD = Huntington’s Disease patients, YTO = estimated years to disease onset, Digit Symbol test is a subscale of the Wechsler Adult 
Intelligence Scale - Revised (WAIS-R), SDMT = Symbol Digit Modality Test, VOSP = Visual Object and Space Perception, VLST = Visual Spatial Learning Test, TMT = Trail Making Test, PAL = 
Paired-Associate Learning, DMTS = Delayed Matching-To-Sample, VSMTS = Visual Search Matching-To-Sample 
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4. Discussion 
This review presents an overview regarding changes of the visual system in premanifest and 
manifest HD gene carriers. Although the visual cortex was not the main focus of many neuroimaging 
studies, there is increasing evidence of early neurodegeneration of the posterior cerebral cortex. 
Based on the current literature, alterations were primarily found in the associative visual areas, such 
as the lingual and fusiform gyri, and the lateral occipital cortex. The cuneus and primary visual cortex 
appear to be affected in more advanced disease stages. As changes of the visual association cortex 
were already detectable in the pre-symptomatic and early disease stages, this implies that the visual 
cortex might be an early marker of disease progression that can be used as an outcome measure in 
disease-modifying intervention trails.  
Clinical visual deficits or visual hallucinations are not commonly reported as typical features of HD. 
Still, studies assessing visual cognitive function in HD report impairments in several domains, 
specifically tasks involving visual object perception, facial emotion recognition and visuospatial 
processing and working memory.  
Studies assessing driving competence in HD patients also showed that visual processing speed, visual 
scanning, and visual attention are more sensitive predictors of performance on on-road driving 
assessments, compared to motor functioning.83,84 
The assessment of visual cognitive impairment is therefore of clinical importance as it can have 
implications in daily functioning, such as the impact on driving performance, the use of electronic 
devices and subsequently affects participating in social activities. For example, the impairment to 
recognize negative facial emotions, such as anger, disgust and fear, could affect communication and 
social relationships.68 Also, patients with HD might have a higher risk of falling or experience 
difficulty with walking because of visual perceptual and visuomotor deficits. In addition, visual 
cognitive impairment can influence overall cognitive performance.  
Visual cognitive impairments have primarily been found in the manifest disease stage, although 
visuospatial working memory deficits and changes in facial emotion recognition are also reported in 
HD gene carriers prior to clinical motor onset. Neuropsychological studies in HD patients, however, 
have used heterogeneous cognitive batteries to examine visual cognition involving various visual 
skills, making a direct comparison between studies difficult. This was particularly found in studies 
assessing visual attention in HD, where the Map Search, TMT part A, SDMT, Stroop, Digit Symbol 
task, Line Bisection test and Cancellation task were all used to measure visual attention. A 
standardized battery of cognitive tasks focusing on visual processing skills might provide more 
information regarding the specific underlying deficits. Using cognitive tasks with minimal motor 
 25 
involvement is recommended to reduce the possible influence of other HD related signs, such as the 
Visual Object and Space Perception battery, the Visual Spatial Learning test and the Stroop tasks.  
Visual cognitive impairment in HD gene carriers has previously been interpreted as a result of 
disturbances in the fronto-striatal network.57,63,80 However, more recent studies suggest that 
degeneration of cortical-striatal circuits that are linked to the associative cortical regions in the 
parietal lobe contribute to visual memory and visuospatial impairments associated with HD.77,79 
We believe that the posterior cerebral cortex is one of the first cortical areas that undergoes 
changes in early stages of HD. Therefore, systematic and preferably longitudinal assessment of the 
visual cortex in HD is warranted, to improve the understanding of structural and functional 
alterations in the visual pathway in patients with HD.  
Linking structural changes of the visual cortex with functional cognitive decline over time can 
provide valuable information on disease progression and cortical degeneration. The use of a 
standardized battery of visual cognitive tasks might additionally provide more detailed information 
regarding impairments in specific visual domains. To reduce interference on task performance, we 
are of the opinion that visual neuropsychological tasks should be selected that are not influenced by 
motor speed, bradyphrenia or language skills.  
To summarize, based on the current literature, early involvement of the visual cortex in the 
neurodegenerative process in HD has been reported. Structural, metabolic, and functional changes 
are primarily found in the associative cortices, such as the cuneus, lingual gyrus, and fusiform gyrus. 
Further research is nevertheless required to provide more insight into the pathophysiological 
changes of the posterior cerebral cortex in HD. Clinical visual deficits or visual hallucinations are not 
commonly reported as typical features of HD. However, visual cognitive impairments are seen in 
several domains, specifically tasks involving visual object perception, facial emotion recognition and 
visuospatial processing and working memory were impaired in pre-symptomatic and early disease 
stages. Because heterogeneous cognitive batteries were used, a direct comparison between studies 
was difficult. We are of the opinion that tasks with minimal motor involvement are most 
recommended for the assessment of visual cognitive function in future clinical trials, such as the 
Visual Object and Space Perception battery, the Visual Spatial Learning test, and the Stroop tasks. In 
addition, a motor task without a visual component, such as the Paced Tapping task, can be included 
in the test battery as a general proxy for disease progression.75 In this way, the relationship between 
visual task performance and visual cortical changes can be measured exclusively.13,75 Investigating 
the association of brain structure and function with visual cognition in HD using a standardized visual 
cognitive battery and different imaging modalities can quantify alterations and hopefully link 
structural posterior brain changes to functional impairments. 
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